Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 156 Jul 27 – Oct 24, 2026
- Disclosed funding
- $5.9B 121 disclosed amounts
- Median round
- $24M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| PT PANDA TherapeuticsCompany profile PANDA Therapeutics develops an antibody-based platform targeting protein aggregates involved in Alzheimer’s disease. PANDA Therapeutics develops an antibody-based platform targeting protein aggregates involved in Alzheimer’s disease. | CHF 100K | Venture Kick Stage IIIUndisclosed | Biotech | Switzerland | Investors | |
| A Develops oligonucleotide therapeutics targeting chronic hepatitis B | $120M | Series CSeries C+ | Biotech | United States | Investors | |
| PT ProFound TherapeuticsCompany profile Uses AI and proteomics to discover drug targets and biomarkers for preeclampsia and eclampsia Uses AI and proteomics to discover drug targets and biomarkers for preeclampsia and eclampsia | $35M | StrategicUndisclosed | Biotech | United States | Investors | |
| T TransfyrCompany profile Physical AI platform capturing real-world lab science into machine-readable data Physical AI platform capturing real-world lab science into machine-readable data | $25M | Seed | Biotech | United States | Investors | |
| RT Revier TherapeuticsCompany profile Revier Therapeutics develops small-molecule medicines targeting class IIa HDAC enzymes for cardiometabolic diseases. Revier Therapeutics develops small-molecule medicines targeting class IIa HDAC enzymes for cardiometabolic diseases. | €6M | Seed | Biotech | Germany | Investors | |
| AB Adaptyv BioCompany profile Adaptyv Bio runs automated laboratory experiments that help protein designers test their sequences and use measured results to improve the next design. Adaptyv Bio runs automated laboratory experiments that help protein designers test their sequences and use measured results to improve the next design. | $40M | Series A | Biotech | Switzerland | Investors | |
| AT Airway TherapeuticsCompany profile Airway Therapeutics develops biologic drug candidates for respiratory, inflammatory and infectious diseases. Airway Therapeutics develops biologic drug candidates for respiratory, inflammatory and infectious diseases. | $24M | Series E-2Series C+ | Biotech | United States | Investors | |
| O OmicsBankCompany profile Connects fragmented hospital data for drug development and healthcare AI research Connects fragmented hospital data for drug development and healthcare AI research | $2.3M | Seed | Biotech, Healthtech | United States | Investors | |
| PT Pixelgen TechnologiesCompany profile High-throughput platform mapping molecular cell architecture at nanoscale resolution High-throughput platform mapping molecular cell architecture at nanoscale resolution | $15.5M | Series B | Biotech | Sweden | Investors | |
| KI KaliVir ImmunotherapeuticsCompany profile Develops oncolytic immunotherapies for patients with advanced solid tumors Develops oncolytic immunotherapies for patients with advanced solid tumors | $14M | Series A | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jul 27, 2026
- 1Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
10rounds0led - 2RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
9rounds3led - 3Y Combinator (YC)
Molagri, Sensible Biotechnologies, WonderTx
6rounds0led - 4Catalio Capital Management
BigHat Biosciences, Basecamp Research, Enveda
6rounds2led - 5Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
5rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.